On September 4, 2019 Accuray Incorporated (NASDAQ: ARAY) reported that the Company will host an Investor Meeting during the American Society of Radiation Oncology (ASTRO) Annual Meeting, being held in Chicago, IL (Press release, Accuray, SEP 4, 2019, View Source [SID1234539291]). The presentations will commence at 3:00pm CT (4:00pm ET/1:00pm PT) and will conclude at 5:30pm CT (6:30pm ET/3:30pm PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program will include presentations by Accuray’s senior management team and clinical key opinion leaders about the Company’s solutions for addressing today’s cancer challenges and will also include question and answer sessions. The topics being discussed include: Solutions for Today’s Market, the Radixact System and the advanced Synchrony Motion Tracking and Correction Technology1, the CyberKnife System and CyberKnife VOLO Optimizer Technology, and U.S. Reimbursement Developments.

Due to the limited space, guests must register to attend Accuray’s ASTRO investor meeting. Please RSVP to Michael Polyviou at [email protected] by Monday, September 9, 2019.

For those not attending the ASTRO meeting, a webcast will be available on the Investor Relations page of the Company’s website at View Source A replay of the webcast will also be available on the Company’s website following the event.

On September 4, 2019 ImaginAb Inc., a clinical-stage immuno-oncology imaging company, reported that it is scheduled to attend and / or present at the following investor and scientific conferences in September and October 2019 (Press release, ImaginAb, SEP 4, 2019, View Source [SID1234539259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

World Molecular Imaging Congress 2019

September 4-7, 2019, Palais des congrès de Montréal, Montréal, Canada

Dr. Anna Wu, Ph.D., Founder and Chief Scientific Officer, will be attending and hosting meetings.

ESMO Congress 2019

September 27 – 1 October, 2019, Fira Gran Via, Barcelona, Spain

Dr. Anna Wu and Dr Toni Ribas, Ph.D., ImaginAb Science Advisory Board Member and President-Elect for The American Association for Cancer Research (AACR) (Free AACR Whitepaper), will be attending and hosting meetings. In addition, ImaginAb’s commercial team led by Ivan Plavec, Chief Business Officer (CBO), will be hosting meetings and available at the ImaginAb Booth #477.

Cavendish Global Conference: The 2019 Phoenix BioHealth Impact Forum

October 2-3, 2019, University Of Arizona – Phoenix Biomedical Campus, Phoenix, AZ, USA

Ian Wilson, CEO, will be attending and hosting meetings.

2nd Annual Advances in Immuno-Oncology USA Congress

October 8-9, 2019, DoubleTree by Hilton Hotel, San Diego, CA, USA

Ian Wilson, CEO, will be chairing a Panel Discussion on ‘Technological Challenges In Clinical Studies’ on October 9 at 13.30 PDT, Room 4.

Ian Wilson will also be presenting a session on ‘Insights on Reverse Translation for Patient Stratification in Clinical Studies’ on October 9 at 16.30 PDT, Room 4.

This follows CBO Ivan Plavec’s Pre-Congress Webinar on August 29, 2019, entitled ‘How CD8 Imaging Is Useful To Pharma Regarding Drug Research And Clinical Decision Making’ which is available to download here.

Optimum 11th Annual Healthcare Investor Conference

October 17, 2019, Bloomberg Headquarters, 3 Queen Victoria St, London, UK

Ian Wilson, CEO, will be attending and hosting meetings along with ImaginAb Board Director and Non-Executive Director at NICE, Tim Irish.

For further information please contact:

ImaginAb

Ian Wilson, Salli Walker
Email: [email protected]
Phone: +1 310 645 1211

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Manel Mateus
Email: [email protected]
Phone: +44 20 3950 9144

On September 4, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, reported a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center (Press release, IMV, SEP 4, 2019, View Source [SID1234539275]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this collaboration, IMV and The Wistar Institute will partner to develop a targeted T cell therapy against the common BRAF cancer mutation, based on peptides identified by the Herlyn lab. Mutations in this gene are the most frequently identified cancer-causing mutations in melanoma and have been identified in various other cancers, including non-Hodgkin lymphoma, colorectal cancer, thyroid cancer, and non-small cell lung and ovarian carcinomas1.

"We are pleased to initiate this collaboration with The Wistar Institute, a world leader in biomedical research and early-stage discovery science with highly relevant expertise to our shared goals in the development of novel treatments for cancer. In particular, Dr. Herlyn has transformed the scientific understanding of stem cells as they relate to cancer and his work in melanoma serves as the basis for numerous therapies now in clinical trials or recently approved," said Frederic Ors, IMV’s Chief Executive Officer. "We believe that cancer-driving mutations, like BRAF, which are directly involved in malignant processes and do not easily escape the immune system, represent an exciting new avenue for targeted T cell therapies. We look forward to working with Dr. Herlyn and his team, leveraging our DPX platform to explore the therapeutic potential of this target in melanoma and other cancers."

"Small-molecule inhibitors of BRAF have shown to be very effective targeted cancer therapies, but with limited long-term benefit due to the onset of therapy resistance. Alternative strategies with emerging therapeutic approaches are needed for the successful long-term treatment of cancers with the BRAF mutation," said Dr. Herlyn. "Immunotherapy could provide a more effective mechanism to target these mutations and we are excited to collaborate with IMV, as its DPX technology enables us to develop targeted T cell therapies aimed at BRAF to test and validate this important hypothesis."

The project scope includes optimizing the DPX formulation with the BRAF peptides and testing the investigational T cell therapy in the pioneering pre-clinical research models at Wistar. As part of the collaboration agreement, IMV holds an exclusive option to in-license intellectual property related to the program.

On September 4, 2019 Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI;OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, reported that Jesse Ledger, Nuvo’s President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City (Press release, Nuvo Pharmaceuticals, SEP 4, 2019, https://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-to-present-at-hc-wainwright-global-investment-conference-300911283.html [SID1234539292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nuvo Presentation Details

Date:

Tuesday, September 10, 2019

Time:

5:00 p.m.

Location:

Lotte New York Palace Hotel

A link to the live audio webcast of the presentation will be available on the Home Page of the Company’s website at www.nuvopharmaceuticals.com. The archived webcast will be available for 30 days.

Mr. Ledger will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the Company should contact conference coordinators to arrange an appointment or contact Nuvo directly via email at [email protected].

On September 4, 2019 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock") (Press release, Avid Bioservices, SEP 4, 2019, View Source [SID1234539260]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The quarterly dividend on the Series E Preferred Stock is payable on October 1, 2019 to holders of record at the close of business on September 16, 2019.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from July 1, 2019 through September 30, 2019. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "CDMOP".